From Pfizer Research to a New Leukemia Drug: One Scientist’s Career

A potential treatment for acute myeloid leukemia is now in Phase 1 testing at Rgenta Therapeutics, a company co-founded in 2020 by a former Pfizer researcher. Its progress reflects the long path from scientific training to drug discovery—and the financing required to move a candidate into human trials.

A winding route into chemistry

The scientist at the center of this story had a difficult start. As a teenager in the 1980s, he struggled in school and was affected by a traumatic experience involving his family. A close friend and that friend’s family helped give him a steadier direction. He became a strong high school football player, then took a summer job at a cheese factory. The work helped him see that he wanted a different future.

His academic performance improved, and after high school he went to college with his friend. He earned a Bachelor of Science in Chemistry from the University of Wisconsin Oshkosh in 1993, followed by a Ph.D. from the University of Utah in 1998. He stayed at Utah for a postdoctoral fellowship with Professor Gary E. Keck.

He met his future wife while studying in Utah. She is also a chemist with a Ph.D. They later raised two daughters together. Their shared scientific training would also shape the next stage of their careers: both moved to Connecticut after taking jobs at Pfizer.

Drug discovery at Pfizer

He joined Pfizer as a research scientist and was promoted to research fellow in 2012, then to drug discovery design lead. During his time there, his work included compounds aimed at Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder, narcolepsy and allergic rhinitis.

His record includes more than 90 patents, publications and external presentations, as well as nearly 40 scientific papers. Two of his articles were among the most cited in their respective areas; one appeared in ACS Chemical Neuroscience and was cited frequently between 2010 and 2014. He also received several company awards, including the W.E. Upjohn Award for innovation.

That work illustrates how a drug discovery career can span many stages: advanced education, laboratory research, design of candidate compounds, scientific publication and collaboration across teams. A promising compound still has to clear further research milestones before it can become a treatment. The scientist’s experience across several disease areas gave him a broad base for that work, but each candidate brings its own scientific questions.

From a large company to a startup

After Pfizer reduced funding for his department, he moved to Aquinna Pharmaceutical, where he served as vice president of research for a couple of years. In 2020, he and a former Pfizer colleague with a Ph.D. co-founded Rgenta Therapeutics. He became chief scientific officer, while his co-founder took the chief executive role.

The company’s acute myeloid leukemia candidate is in Phase 1 of a clinical trial. That is an early point in the testing process, and the source describes it as a potential treatment rather than an established medicine. The trial’s progress will depend on the research results and the company’s ability to continue supporting development.

For a young research company, financing is tied closely to that work. The source says Rgenta depends on investors to fund its ongoing research. Developing a drug takes substantial time and money, and the costs continue as candidates advance through research and clinical testing. Investors accept the risk that a candidate may not reach the market; if a product does succeed, they expect a return for the capital they supplied.

The people and time behind a candidate

The scientist’s training took him close to age 30 before he began earning what the source describes as real money. He supported his education through a mix of grants, scholarships, loans and work. The account does not say how long it took him and his wife to repay any education debt, but it makes clear that a long period of study came before their industrial careers.

That timeline is part of the broader story of medicine development. Scientists spend years learning their fields, and their training continues during their careers as methods and knowledge change. Their work then feeds into research programs that can take additional years to assess. A candidate entering a Phase 1 trial represents one step in that process, with its future still dependent on evidence gathered as development proceeds.

Criticism of pharmaceutical companies also has a place in the discussion. The source points to the opioid scandal as an example of serious misconduct, while arguing that such failures do not erase the contribution of researchers working to treat disease. Both points can stand: misconduct calls for accountability, and the scientific work behind potential treatments deserves attention on its own terms.

For Rgenta, the immediate story is the leukemia candidate’s early clinical stage and the funding needed to keep research moving. For the scientist, it is the culmination of a path from a difficult adolescence through decades of study and drug discovery. The next meaningful marker will be what the ongoing research shows about the candidate’s potential.

My Amazon Author Link